-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC News
-
Study Demonstrates Multidisciplinary Approach Can Improve Care for Elderly Lung Cancer Patients
During the 2024 WCLC, Dr. Shalini Vinod reviewed data showing that a nurse-led care model for geriatric patients outperformed a medical-led model.
-
Taletrectinib Shows Promising Results in Patients with ROS1-Positive NSCLC
Dr. Geoffrey Liu presented results from the TRUST-II trial on the safety and efficacy of taletrectinib in TKI-naive and TKI-pretreated patients.
-
The Art of Science Communications
IASLC Communications Committee members gathered during a WCLC 2024 workshop to share tips on tailoring messages to different audiences, building a strong social media presence, and more.
-
WCLC Closing Plenary Explored Overcoming Barriers to Patient Advocacy Worldwide
Global leaders in patient advocacy assembled during the 2024 World Conference on Lung Cancer to shed light on ongoing initiatives.
-
Data Link Air Pollution Exposure to Oncogene-Driven Lung Cancer Diagnoses
Dr. Yixian Crystal Chen recently presented results that demonstrate fine particulate matter poses health risks, even for those with no smoking history.
-
Study Evaluating Tusamitamab Ravtansine in Patients with Non-Squamous NSCLC is Discontinued
Dr. Benjamin Besse recently discussed detailed findings from the now discontinued CARMEN-LC03 trial.
-
LUMINOSITY Subgroup Analysis Shows Similar Results for Asian Patients Compared to Global Population
Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression.
-
TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort.
-
Climate Change, Pollution, War, and More Increasing Risk, Impacting Management of Lung Cancer Worldwide
Dr. Leticia Nogueira and other experts explored non-tobacco factors that are playing a role in our evolving knowledge during a WCLC 24 plenary session.
-
Artificial Intelligence-Powered Tools May Help Develop Predictive Biomarkers
Dr. Kenneth O’Byrne says research shows novel method for analyzing tissue samples may help predict immunotherapy response.